MitoQ to Improve Vascular Funciton in Preeclampsia
Eligible age
18–50 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.
Sponsor: Medical College of Wisconsin
You may qualify if…
- ✓ Inpatient Cohort
- ✓ pregnant patients with a clinical diagnosis of preeclampsia with severe features
- ✓ gestational age between 23+0 and 32+0 weeks' gestation
- ✓ singleton pregnancy
- ✓ age 18-50 years old
- ✓ No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features
- ✓ Able to consent and follow a 2-step commend
- ✓ English speaking
You may not qualify if…
- ✕ • Unable to stand from chair without physical assistance from another person (able to use assistive device).
- ✕ History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg).
- ✕ Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization)
- ✕ History of head trauma or concussion within the past 6 months
- ✕ Comorbid neurological disorder
- ✕ Peripheral vascular disease
- ✕ Diagnosed myocardial infarction or arrhythmia in the previous year
- ✕ Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg
Where it's recruiting
Milwaukee
Source: ClinicalTrials.gov · NCT07229261 · last updated 2026-05-01